CA2439430C - Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity - Google Patents

Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity Download PDF

Info

Publication number
CA2439430C
CA2439430C CA2439430A CA2439430A CA2439430C CA 2439430 C CA2439430 C CA 2439430C CA 2439430 A CA2439430 A CA 2439430A CA 2439430 A CA2439430 A CA 2439430A CA 2439430 C CA2439430 C CA 2439430C
Authority
CA
Canada
Prior art keywords
extract
activity
tilianin
inflammatory
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2439430A
Other languages
English (en)
French (fr)
Other versions
CA2439430A1 (en
Inventor
Hyeong Kyu Lee
Sei Ryang Oh
Kyung Seop Ahn
Soon Ja Choi
Jung Hee Kim
Goo Taeg Oh
Jung Joo Hong
Seong Kyu Park
Woo Namkung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of CA2439430A1 publication Critical patent/CA2439430A1/en
Application granted granted Critical
Publication of CA2439430C publication Critical patent/CA2439430C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2439430A 2001-02-27 2001-12-20 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity Expired - Fee Related CA2439430C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20010009977 2001-02-27
KR2001/9977 2001-02-27
PCT/KR2001/002224 WO2002074320A1 (en) 2001-02-27 2001-12-20 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity

Publications (2)

Publication Number Publication Date
CA2439430A1 CA2439430A1 (en) 2002-09-26
CA2439430C true CA2439430C (en) 2010-06-22

Family

ID=19706307

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2439430A Expired - Fee Related CA2439430C (en) 2001-02-27 2001-12-20 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity

Country Status (8)

Country Link
US (2) US20040071792A1 (https=)
EP (1) EP1363648B8 (https=)
JP (1) JP4091436B2 (https=)
KR (1) KR100447948B1 (https=)
CN (1) CN100376255C (https=)
CA (1) CA2439430C (https=)
DE (1) DE60124591T2 (https=)
WO (1) WO2002074320A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003030A1 (en) * 2004-07-01 2006-01-05 Lin Chun-Ying Essential oils for treating and/ or preventing allergic disease
KR100807645B1 (ko) * 2006-10-17 2008-02-28 주식회사 유니젠 위장질환 치료 및 예방용 조성물 및 그의 제조방법
KR100851489B1 (ko) * 2006-11-30 2008-08-08 (주)아모레퍼시픽 틸리아닌( ｔｉｌｉａｎｉｎ) 또는아카세틴(ａｃａｃｅｔｉｎ)을 유효성분으로 함유하는화장료 조성물
DE202008011721U1 (de) * 2008-09-03 2008-12-24 American Phoenix Biotech Inc., Hacienda Heights Pflanzliche Zusammensetzung zur Behandlung von Krebs
KR101540310B1 (ko) * 2013-08-07 2015-07-30 건국대학교 산학협력단 방아풀 추출물을 함유하는 신경 염증 예방 및 치료용 조성물, 그리고 방아풀 추출물 추출 방법
CN107429226A (zh) * 2015-01-06 2017-12-01 株式会社露太利温 luterion及其分离和培养方法
PL412214A1 (pl) 2015-05-04 2016-11-07 Biovico Spółka Z Ograniczoną Odpowiedzialnością Kompozycja roślinna o właściwościach przeciwzapalnych, przeciwalergicznych i/lub przeciwastmatycznych oraz jej zastosowanie
KR102049875B1 (ko) 2018-06-29 2019-11-28 충북대학교 산학협력단 에키나세아 배양근 유래 신규 화합물 및 이의 항염증 용도
CN111171094B (zh) * 2018-11-13 2023-06-16 上海医药工业研究院有限公司 一种香清兰苷中间体及其制备方法和应用
US12472221B2 (en) * 2019-05-23 2025-11-18 Korea Institute Of Oriental Medicine Composition for inhibiting osteoclasts containing agastache rugosa extract as active ingredient, and use thereof
KR102339923B1 (ko) * 2019-11-12 2021-12-20 한국한의학연구원 혈행 개선용 식치제호탕 조성물
KR102300732B1 (ko) * 2020-11-11 2021-09-14 주식회사 제이에스무역 난황유 및 배초향 줄기세포를 함유하는 항산화, 미백, 항주름 또는 항염증용 조성물
JP2025143197A (ja) * 2024-03-18 2025-10-01 ペガヴィジョン コーポレーション 皮膚バリア強化及び抗炎症用のカワミドリエキソソーム組成物及びその用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3831196A1 (de) * 1988-09-14 1990-03-22 Bosch Gmbh Robert Elektromagnetisch betaetigbares ventil
CN1060772A (zh) * 1991-10-30 1992-05-06 阳山县食品厂 一种藿香姜计陈皮的生产工艺
CN1057447C (zh) * 1993-01-22 2000-10-18 马军营 一种治疗小儿腹泻的口服液
CN1117388A (zh) * 1994-08-24 1996-02-28 东营市面粉厂 复方柴胡擦剂
JPH08176002A (ja) * 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
KR970007366A (ko) * 1995-07-31 1997-02-21 고제섭 압축단자 접촉저항 측정장치 및 그 방법
CN1151881A (zh) * 1995-12-01 1997-06-18 陶周行 一种阴道冲洗保留剂及其制备工艺与使用方法
CA2272540C (en) * 1996-09-27 2009-09-01 Takeshi Karita Anti-oxidizing composition for scavenging free radicals, pharmaceutical composition comprising the same, and process for preparing the same
US5776462A (en) * 1996-12-10 1998-07-07 Sage R&D, A Partnership Pogostemon cablin extract for inhibiting H. influenzae adhesion and treating otitis media or sore throat
KR100232053B1 (ko) * 1997-04-22 1999-12-01 김동태 DPPH(1,1-diphenyl-2-picrylhydrazyl)를 이용한 항산화물질의 분석방법
JP4231559B2 (ja) * 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
KR100215400B1 (ko) * 1997-05-27 1999-08-16 김진수 건강보조식품용 유중수적형 영양음료 및 그 제조방법
KR100309071B1 (ko) * 1998-09-02 2001-12-17 성재갑 콜라겐합성촉진제를함유한피부용조성물
KR100341798B1 (ko) * 1999-08-04 2002-06-26 대한민국 (관리청:특허청장, 승계청:농촌진흥청장) 방아잎으로부터 로즈마린산을 분리하는 방법
WO2001045725A2 (en) * 1999-12-23 2001-06-28 Ancile Pharmaceuticals, Inc. Treatment for inflammatory bowel disease (ibd) and related conditions
KR100376306B1 (ko) * 2000-08-07 2003-03-17 한완석 혈액순환 촉진용 건강식품 조성물
CN1126453C (zh) * 2000-08-09 2003-11-05 郭兴华 天然抗菌组合物及其应用
CN1282537A (zh) * 2000-08-22 2001-02-07 张益� 一种藿香饮料

Also Published As

Publication number Publication date
CA2439430A1 (en) 2002-09-26
JP4091436B2 (ja) 2008-05-28
US7534456B2 (en) 2009-05-19
CN100376255C (zh) 2008-03-26
EP1363648B1 (en) 2006-11-15
CN1518454A (zh) 2004-08-04
US20080081081A1 (en) 2008-04-03
WO2002074320A1 (en) 2002-09-26
DE60124591T2 (de) 2007-09-06
EP1363648A1 (en) 2003-11-26
EP1363648B8 (en) 2007-04-25
KR100447948B1 (ko) 2004-09-08
EP1363648A4 (en) 2005-02-09
KR20020070062A (ko) 2002-09-05
DE60124591D1 (de) 2006-12-28
US20040071792A1 (en) 2004-04-15
JP2004521933A (ja) 2004-07-22

Similar Documents

Publication Publication Date Title
US7534456B2 (en) Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity
AU2007203186B2 (en) The healthy and functional foods for the obesity patients using purple-colored potato
KR102397916B1 (ko) 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
KR101700348B1 (ko) 까마귀쪽나무 잎 또는 그 열매 추출물을 이용한 관절염 개선용 조성물
KR101965061B1 (ko) 땅콩 새싹 추출물 또는 이의 분획물을 포함하는 대사성 질환의 예방 또는 치료용 조성물
KR101735057B1 (ko) 오스모틴 단백질 또는 오스모틴 펩타이드를 유효성분으로 함유하는 간기능 및 신장기능 장애의 예방 또는 치료용 조성물
KR100865513B1 (ko) 강화약쑥 알코올 추출물을 포함하는 비만의 예방 및 치료용 조성물
KR100291144B1 (ko) 디오스민을 포함하는 동맥경화증 및 고지혈증의 예방 및치료용 조성물
EP1416927A1 (en) Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect
JP4534003B2 (ja) 抗アレルギー作用を有する健康食品
KR100291141B1 (ko) 디오스민을포함하는동맥경화증및고지혈증의예방및치료용조성물
KR100460439B1 (ko) 배초향 추출물이 함유된 식품첨가제
WO2000032214A1 (fr) Agents prophylactiques contre l'hepatopathie
KR20030002972A (ko) 항염증 활성 및 항동맥경화 활성을 나타내는 틸리아닌
KR20210155119A (ko) 풀무치 추출물을 포함하는 비만 예방 또는 치료용 조성물
US20160193180A1 (en) Composition for preventing and treating immune diseases containing daurinol compound as active ingredient
KR100569086B1 (ko) 간세포 보호활성을 갖는 고로쇠 잎 추출물 및 이로부터분리된 페놀성 화합물
KR20020082121A (ko) 플라보놀 유도체를 유효성분으로 함유하는 간염 예방 또는치료용 약학적 조성물
KR20040027100A (ko) 대황 추출물을 함유하는 고지혈증 치료제 조성물
KR101426873B1 (ko) 알디시아 팅크토리아 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
KR20160084990A (ko) 아까시나무 추출물을 함유하는 동맥경화증, 심근경색, 뇌졸중, 혈관성치매, 간질환, 이상지질혈증 또는 혈전증 예방 또는 치료용 조성물
Obeten et al. EVALUATION OF AQUEOUS EXTRACT OF VERNONIA AMYGDALINA ON THE HISTOPATHOLOGY OF THE LIVER OF WISTAR RATS
Lee et al. Research Article Antiatherogenic Effect of Camellia japonica Fruit Extract in High Fat Diet-Fed Rats
JP2003034648A (ja) 生体膜保護剤
KR20140054955A (ko) 결석 제거에 도움이 되는 참가시나무 잎 액기스 제조 방법

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191220